medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

1

2 Trained dogs can detect the odour of Parkinson's Disease

- 3
- 4 Nicola Rooney a,b*, Drupad K Trivedi^c, Eleanor Sinclair ^c, Caitlin Walton Doyle^c, Monty Silverdale^d, Perdita Barran^c, Tilo Kunath^e, Steve Morant^f, Mark Somerville^a, Jayde Smith^a, 5 6 Julie Jones-Diette^a, Jenny Corish^a, Joy Milne^c, Claire Guest^a 7 8 ^a Medical Detection Dogs, 3 Millfield, Greenway Business Park, Winslow Road, Great 9 Horwood, Milton Keynes, MK17 ONP. ^bBristol Veterinary School, University of Bristol, BS40 5DU 10 11 ^c Manchester Institute of Biotechnology, Department of Chemistry, The University of 12 Manchester, 131 Princess Street, Manchester, UK, M1 7DN 13 14 ^d Department of Neurology, Salford Royal Foundation Trust, Manchester Academic Health 15 Science Centre, University of Manchester, Manchester, U.K., M6 8HD 16 ^eInstitute for Stem Cell Research, School of Biological Sciences, The University of Edinburgh, 17 Edinburgh UK, EH16 4UU 18 19 ^fDivision of Molecular and Clinical Medicine, University of Dundee, DD1 4HN. 20 21 22 Running title: Dogs can detect the odour of Parkinson's Disease 23
- 24 Correspondence address:
- 25 Animal Behaviour and Welfare Group, Bristol Veterinary School, Langford, UK. BS40 5DU
- 26 Tel : +44 (0) 117 455 0785 nicola.rooney@bristol.ac.uk
- 27

28 Abstract

29 A definitive diagnostic test for PD remains elusive, so identification of potential biomarkers may 30 shed light on methods for diagnosis and facilitate early intervention. Excess sebum secretion and 31 skin pathology are recognised symptoms of early PD. It is likely these result in a unique signature of 32 volatile organic compounds that could be used to identify early stages of disease. Numerous medical 33 conditions produce distinctive odours, and dogs have been trained to detect many of these. A single 34 previous study, suggested that dogs can also be trained to detect Parkinson's Disease. In this study, 35 two dogs were trained to distinguish sebum swabs obtained from drug naïve, and medicated 36 Parkinson's patients from swabs from control participants. After 38-53 weeks of training on 205 37 samples (90 target and 115 control), the dogs were tested in a double-blind trial using 60 control and 38 40 target samples from drug-naïve patients. The dogs both showed high sensitivity (proportion of 39 target samples found 70% and 80%) and specificity (proportion of control samples not alerted to 40 90% and 98%) of alerting response. This trial supports previous findings that dogs can be trained to 41 reliably detect the odour of PD. We suggest there is a potential for dogs to achieve even higher accterative within the personal sector and a personal processing and a personal and the sector and a personal and the sector and a personal processing and the sector and 42

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

- prior to diagnosis, as well as hard to diagnose PD cases. Further exploration of the factors which 43
- 44 affect dogs' sensitivity and specificity and sample features which affect accuracy of discrimination
- 45 are now required.
- 46

47 Keywords: dogs, sensitivity and specificity

- Introduction 48
- 49 Parkinson's disease (PD) is a neurological disease that causes progressive motor symptoms including
- 50 tremor, stiffness and slowness of movement, as well as non-motor symptoms including mood
- 51 problems, cognitive issues, sleep disturbance and pain. Neurodegeneration, predominantly in the
- 52 central nervous system is the cause to these widespread symptoms. At Braak stage 3, the Substantia
- 53 Nigra becomes affected, leading to a reduction in dopamine production in the brain, a chemical that
- is vital for the control of movement Error! Reference source not found. As progression of the disease can be 54
- 55 slow, often with only very minor symptoms initially, it is difficult to definitively diagnose PD
- 56 particularly in the early stages. Early motor and non-motor symptoms, may result in people being
- diagnosed with a range of other conditions including rheumatological, neurological, sleep and mood 57
- 58 disorders². Even as the disease progresses, it can be difficult to differentiate from other Parkinsonian
- 59 disorders³. Early and accurate diagnosis is vital, to allow patients to benefit from pharmacological 60 interventions, such as a levodopa/carbidopa, which may be more effective when administered
- 61 early⁴. Non-pharmacologic interventions, such as exercise, are also easier for the patient to perform
- 62 before declines in locomotor skills and movement occur⁴.
- 63 Around 1 in 500 people in the UK are affected by PD, a prevalence of approximately 127,000 in 2017
- ⁵. Gumber et al. (2017) suggests an economic burden to the NHS of £2,118 per person with 64
- 65 Parkinson's (PwP), hence the total UK annual cost could be in excess of £268 million per year ⁵. With
- 66 an aging population and rising demand for health services, this will create a significant challenge for
- 67 healthcare providers. Research is needed to support treatment decisions, direct prevention
- 68 strategies, raise awareness, and avoid unnecessary and expensive repeat admissions between home
- 69 and hospital.
- 70 Studies that aid our understanding of early symptoms could help develop early diagnosis are
- paramount. Much research has attempted to identify new biomarkers⁶, particularly those that may 71
- 72 predict whether someone will develop PD in the future.⁷ One early non-motor symptom, is
- 73 seborrheic dermatitis: excessive sebum (waxy or oily secretion) which is excreted from the
- sebaceous glands at higher quantities in patients with PD^{8,9}. Sebum has been noted to have a very 74
- distinctive odour identified in repeated blinded studies with human super-smeller Joy Milne, who 75
- 76 has hyperosmia. This could potentially be used as an indicator for the disease ¹⁰ and is associated
- 77 with lipid dysregulation consistent with many PD studies¹¹.
- 78 Many medical conditions have distinctive odours ^{12,13} including cancer ¹⁴ and schizophrenia ^{15,16}.
- 79 Health care workers have reportedly used scent to triage illness, and in studies as early as 1960,
- 80 when it was shown that sweat from schizophrenic and non-schizophrenic patients could be
- distinguished by trained rats using odour alone¹⁷. There is a growing body of evidence that disease-81
- 82 specific volatile organic compounds (VOCs) could be used for the early detection of disease before
- more obvious clinical signs or symptoms become apparent¹⁸. The mechanism for the release of 83
- volatiles is not well studied and varies with disease. However, small amounts of volatile organic 84
- 85 compounds are released through metabolic processes and can be identified in the secretions of
- sweat, mucus, sebum, urine, blood and breath ¹⁹. 86

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

87 The olfactory capability of dogs to detect diseases is well-established ²⁰. For over twenty years, the UK charity Medical Detection Dogs (MDD) has trained dogs to detect human diseases ranging from 88 prostate cancer ²¹ to malaria ²² and Covid-19 ^{e.g. 23}. MDD has also trained assistance dogs to alert to 89 90 the onset of life-threatening episodes for people living with chronic diseases such a Type 1 diabetes

²⁴⁻²⁵. It therefore seems extremely plausible that dogs could be trained to alert to the odour of PD. 91

A recent prospective, diagnostic case-control study was conducted in China²⁸. Three dogs trained in 92 93 a laboratory were tested on sebum samples from PD medicated and drug naïve patients, and 94 matched controls. The diagnostic criterion applied was that at least two of the three dogs alerted to 95 the sample and, using this criteria, the study saw sensitivity and specificity rates of 91% and 95% to

96 medicated and 89% and 86% to drug naïve samples, respectively. The authors concluded that

97 trained dogs could be a useful, quick non-invasive and cost-effective method to identify patients

98 with PD during community screening and health check-ups as well as within neurological practice,

99 but provide limited information on the dog's training and testing.

100 In the current study, we further tested the capacity of trained dogs to discriminate the odour of Parkinson's disease from controls using sebum swabs. Since the dog is effectively the measuring 101 102 instrument, it is important to provide full details of its training, calibration and testing which we

describe fully. To simulate real operations, unlike Gao et al ²⁸, we did not use precisely matched 103

control samples. However, since it is vital to minimise all possible confounding factors e.g. 29 we 104

105 trained the dogs using samples taken from drug naïve (DN) patients shortly after diagnosis and a

106 control group ranging from healthy individuals to patients with other neurological conditions. We

started with ten potential dogs, and based on their performance during initial training, we selected 107

108 two dogs, which were trained by a professional dog trainer (MS) using an established protocol ²¹ and

- 109 then tested during double-blind trials.
- 110

111 Materials and Methods

- 112
- 113 **Ethical Review**

Ethical approval for this project (IRAS project ID 191917) was obtained by the NHS Health Research 114 115 Authority (REC reference: 15/SW/0354).

- 116
- 117

118 Participant Recruitment

119 Parkinson's disease patient and control participant samples were collected during a nationwide

recruitment at 25 different NHS clinics as described in Trivedi et al. ¹⁰. The participants for the 120

current study were selected at random from those collected for that study, in order to match 121

phenotypes as closely as possible for both training and testing. Those used for testing were all drug 122

123 naïve, whilst medicated patients were also used in the latter stages of training. The control samples

124 were collected from people accompanying PwP in clinics at the same sites and additional control

125 samples came from volunteers attending the Medical Detection Dog centre.

126

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Sample collection 127

- 128 All participants were asked to avoid showering, use of cosmetics and fragrances for 24 hours prior to
- 129 sample collection to minimise contamination from washing cosmetics. Sampling followed the same
- 130 standard operating procedure for disease and control study volunteers. Sebum was sampled from
- 131 volunteers by wiping a square piece of medical gauze along the hairline, down the nape of the neck
- 132 and across the shoulder, this was performed by a clinician for samples taken in NHS clinics and by
- 133 the volunteer themselves for other controls. The upper trunk was selected as it is a sebum rich
- 134 location and during pilot method development studies, this area was indicated by human super
- smeller to have highest odour linked to PD¹⁹. The gauze samples were bagged individually and 135
- sealed in an airtight, minimal odour, plastic bag which was labelled with the participants' 136
- 137 anonymised code. Samples were shipped to a central Manchester facility and stored at -80°C within 138 24 hours of arrival.
- 139 From here the samples were transported on dry ice to the dog training centre accompanied by a
- 140 recruitment cohort code, participant sex, age, BMI, ethnicity, medical conditions, current
- 141 medications, drinking and smoking behaviour (obtained from a questionnaire that participants filled
- 142 in at the time of sampling) and whether they were a control or patient. For patients, further
- 143 information was provided on date of diagnosis, and medications they were taking for PD. All samples
- were stored at -80 °C. 144
- 145 In total, 130 samples were collected from PD patients and 175 from control and these were
- randomly divided into 105 training and 100 testing samples. All samples were cut in half ahead of 146
- 147 storage. Duplicate samples were either both used within the training samples, or one was used as a
- training sample, and the other as a "filler" control during testing, to enable lines of four samples to 148
- 149 be presented but the dogs' response to any "familiar" samples during testing was not analysed. The
- 150 training samples were labelled as positive or control, but the test samples were given only a code, so
- 151 testing was totally blind.
- 152 Canine Disease Detection Training
- 153 After initial screening of ten dogs, five were deemed to have potential aptitude and hence
- 154 commenced initial PD training.
- 155 A training protocol was used which increased in difficulty over time. In Phase 1, the target scent was
- 156 introduced to the dog, and the dog rewarded for showing a behavioural change in response.
- 157 Individual dogs naturally show different behaviours, and these were rewarded by their trainers, so
- 158 each dog gave a consistent behaviour e.g., sit or stand and stare, thereafter terms an indication.
- 159 Correct responses were rewarded with food or ball-play, in conjunction with the use of an audible
- 160 clicker (used as a secondary reward).
- 161 Initial training used search and find games, then dogs were trained to walk along a line of four
- 162 stainless steel stands, one metre apart, each with an arm holding a 40 ml glass jar containing a swab
- 163 sample. A stainless-steel grill was placed over the mouth of each jar to prevent the dog touching the
- 164 sample. After each line was searched, the plates were cleaned in an ultrasonic cleaner with an
- 165 enzymatic solution (Reprozyme TM, NVS Stoke-on- Trent UK), the plates were rinsed thoroughly
- 166 using a commercial glass washer (minimum 85 °C) then left to air dry to avoid any contamination.
- 167 The jars were cleaned in the same way but additionally were placed in an oven at 180-C for 20
- 168 minutes.
- 169 The dog was trained to sniff each of the four stands in order. Their behaviour at each stand was
- 170 recorded on a database as IND (indicated), HES (hesitated), INT (interest, but weaker than HES), NI

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

- 171 (no interest) or NS (not searched, usually because a sample earlier in the line was indicated). Initially
- dogs were presented with one positive sample and three control samples during each run. As
- training progressed, lines with four controls were also presented. Dogs were rewarded for both
- 174 indicating positive target samples and for searching a negative line without an indication. Once dogs
- 175 were reliably indicating positive target samples against control samples taken from participants with
- 176 non-neurological conditions, we added control samples taken from patients with diseases with
- similar symptoms to Parkinson's disease, including depression, anxiety, bi-polar disorder, epilepsy,
- 178 stroke, hypothyroidism and migraine. Later training also included medicated (as well as drug naïve)
- target samples to ensure dogs were discriminating entirely based on PD status.
- 180 As training progressed, three of the dogs failed to learn the task, and hence were rejected from
- training. Only the data from the two remaining dogs is presented here. They were a two-year old
- male Golden Retriever (Dog 1) and a three-year old male Labrador x Golden Retriever (Dog 2).
- 183 In total, we used 205 samples during training; 90 targets and 115 controls. Dog 1 took part in 72
- 184 training sessions over 38 weeks and encountered control samples on 1683 occasions and target
- samples on 597 occasions. Dog 2 took part in 83 sessions over 53 weeks and encountered control
- 186 samples on 1759 occasions and target samples on 582 occasions. Each training session lasted an
- average of 21 minutes and a maximum of 69 minutes. On three occasions during training, both dogs
- indicated in response the same control sample, and in these cases the sample was withdrawn from
- 189 the training process.

190

- 191 Canine Disease Detection Testing
- 192 The two dogs that were deemed to have learnt the task adequately, proceeded to a double-blind
- randomised controlled trial and were presented with 100 previously unseen samples, of which 40
- 194 were from individuals with confirmed disease (positive for PD). Due to the scarcity of controls, we
- used an additional 100 duplicates of control samples seen by the dogs during training. These were
- used as "fillers" to facilitate presenting lines of four samples, but the dogs' responses to these
- 197 familiar samples were not included in any analyses.
- 198 The samples were presented in the same way as during training in a four-stand alignment. In each
- 199 "run" there was either one or no positive samples. Both the trainer/handler and the experimenter
- were blind to the presence and position of any targets. Ten control and five positive samples from
- the training set were used for calibration runs, to confirm the dog was focused on the scent.
- 202 Calibration runs were requested at any time by the trainer, were unblinded and their results were
- 203 not included in the analysis.
- 204 The regular trainer guided the dog to search each line of samples. Dogs were permitted to make a
- 205 maximum of four passes over the line. Once the handler was confident of the dog's choice, a
- 206 decision was communicated to the experimenter. For each the dogs' behaviour was coded as it was
- during training (IND, HES, INT, NI or NS), with HES, INT and NI all being treated as a negative
- 208 response for analysis.
- 209 Each line of samples was presented in reverse order on a second occasion, so that samples for which
- 210 no decision was made in the first run re-presented. Any samples that were still not seen after this
- run were collected together in new lines, until a decision had been made for all samples. This
- 212 process resulted in some samples being encountered more than once by the same dog, however we
- 213 only analysed their response on first encounter.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

214

- 215 Data Management and Analysis
- A blinded experimenter entered the responses to each sample into the database. All trial samples
- 217 had previously been given a "blind ID" which was read by the data collection software to determine
- 218 whether responses were correct. The software revealed whether each response was correct, and if
- so, the trainer was asked to reward their dog. If any sample was incorrect, no reward was given. The
- 220 database was password protected and only the trial statistician (SM) knew both passwords prior to
- trial completion.
- 222 We used the first encounter with each of the 100 novel samples to calculate sensitivity (proportion
- of target samples found) and specificity (proportion of control samples that were not alerted to) for
- 224 each dog. We also tested whether there was any association between the errors made by each dog,
- 225 examining target and control samples separately using Fishers Exact tests.
- 226
- 227 Results
- 228 Training
- 229 The performance of two dogs during training was deemed satisfactory. In its last 10 training sessions
- 230 Dog 1 responded correctly to 91% of encounters and Dog 2 responded correctly to 90% of
- 231 encounters.
- 232
- 233 Testing
- Both dogs demonstrated an ability to discriminate between the PD positive and control samples they
- had not encountered before (*P*<0.0001), with sensitivities of 70.0% and 80.0% and specificities of
- 236 90.0% and 98.3% (Table 1).
- 237

Table 1. Sensitivity and specificity of two dogs in double-blind trials

239

	Samples		Indications		Sensitivity and specificity with confidence intervals (%)	
	Туре	n	Number indicated	% indicated (as PD)		
Dog 1	Control	60	6	10.0	Specificity 90.0 (79.5, 96.2)	
	Positive	40	28	70.0	Sensitivity 70.0 (53.5, 83.4)	
			p<(0.0001		
Dog 2	Control	60	1	1.7	Specificity 98.3 (91.1, 100.0)	
	Positive	40	32	80.0	Sensitivity 80.0 (64.4, 91.0)	
			p<(0.0001		

control samples.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

- 241 Agreement between the two dogs was higher than expected by chance for positive samples: 7 were
- 242 missed by both dogs (expected 2.4) and 27 were indicated by both dogs (expected 22.4). Agreement
- 243 between the dogs for control samples was close to expectation.
- 244 Table 2. Agreement between responses of the two dogs during double blind testing p-values for
- 245 Fisher's exact tests. Numbers in brackets are the expected numbers if there were no correlation
- between the dogs' responses. 246

Positive samples			No	Yes	Total
	Indicated	No	7 (2.4)	1(5.6)	8
	by Dog 2	Yes	5 (9.6)	27 (22.4)	32
		Total	12	28	40

247

Control samples			No	Yes	Total
	Indicated	No	54 (53.1)	5 (5.9)	59
	by Dog 2	Yes	0 (0.9)	1 (0.1)	1
		Total	54	6	60
		-	m-0.1(200	

p=0.1000

p=0.0003

Indicated by Dog 1

248 Discussion

This study confirms the previous findings of Gao et al ²⁸ that dogs can be trained to discriminate 249

250 between Parkinson's patient and control sebum swab samples. Although only two dogs from the

251 initial ten trialled were deemed suitable to progress to full training, the subsequent performance of

252 these during training and double-blind testing demonstrates that it is possible for dogs of the correct

- 253 aptitude to learn the task.
- 254 The two dogs achieved high sensitivity and specificity, when trained using ex-situ sebum samples,

255 showing there is an olfactory signature which is different in patients with Parkinson's Disease. Since

256 increased sebum secretion has also been noticed before motor signs of PD ^{30, 31} this suggests that

257 detection of biomarkers in sebum could lead to early diagnosis and intervention.

- 258 Agreement between dogs was higher than would be expected by chance, suggesting that some
- 259 samples were easier to identify than others. There were several samples to which both dogs

260 incorrectly indicated. Although initial inspection of sample details suggested no obvious

- 261 commonalities between these samples, further research is required to understand which features of
- 262 the sample are responsible for these differences.
- Sensitivity levels of 70 and 80% are high; well above chance and comparable to levels seen for 263
- example in malaria detection ²², and considerably higher than those obtained when using dogs to 264
- detect some other medical conditions (e.g., 41% bladder cancer²¹). The only other study examining 265
- 266 detection of PD by dogs, obtained higher sensitivity (91%), but similar specificity (95%) as seen here
- 267 (98% and 90%).
- 268 There are multiple plausible reasons for the difference in sensitivity between the two studies; Gao et
- al ²⁸ used consensus responses of two out of three dogs as the detection criterion ²⁸ whilst our 269
- 270 analysis took each of two dog's responses individually. Gao's testing protocol used PD samples and

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

six perfectly matched controls, whilst ours included controls that were not precisely matched which 271

- 272 may make the task harder for the dogs, but we deem this to be more authentic. Gao et al also
- 273 presented a known PD target to the dogs ahead of each testing run so dogs were able to "match to 274 source", which may improve their detection but may not be practicable in an operational setting.
- 275 The value of this procedure is yet to be determined and is an important area of future study. Gao's
- 276 dogs had been trained on PD over a period of two years, whilst ours were trained for less than a
- 277 year, although the number of samples encountered during training was not described by the Gao at
- 278 al., so cannot be compared There were several other details of the dog testing methods which were
- 279 not described by Gao et al, such as the period over which testing occurs, or a description of the
- 280 "tanks" in which samples were presented, which precluding further comparisons. However, the
- studies together suggest that refinements to training and sample presentation in the future could 281
- 282 lead to further increases in detection accuracy.
- 283 In our study, whilst the specificity of Dog 2 was 98% reflecting very few false alerts, and similarly the
- dog showed the highest sensitivity (80%), Dog 1 showed slightly lower specificity (90%) and a 284
- 285 sensitivity of only 70%. These differences may reflect personality differences between the two dogs,
- 286 with Dog 1 showing a more liberal approach to responding; a higher tendency for false alarms thus
- minimising false negatives to increase the chance of a hit ³². Or it may reflect subtle differences in 287
- 288 their training, leading Dog 2 to be more precise in its responses. Further analysis using the data
- 289 stored during training, will enable understanding of the extent to which these individual differences 290 develop or are consistent from early training.
- In conclusion, the sensitivity and specificity of dogs trained to find PD positive samples is 291
- 292 encouraging and supports previous finding that further research has the potential to help develop
- 293 methods for the early diagnosis of PD, by dogs or by other technology. This may in turn lead to
- opportunities for earlier intervention than is possible at present and be especially beneficial for hard 294
- 295 to diagnose cases of PD. Longitudinal studies of dogs' capacity to alert prior to formal diagnosis are
- 296 now required.
- 297
- 298 Acknowledgements including source of funding
- 299 We thank Michael J Fox Foundation and Parkinson's UK for funding this study. We also thank the
- 300 nationwide NIHR recruitment centres for their support and would like to thank the patient's carers
- 301 and participants for providing the samples. We are very grateful to all the participants who took part
- 302 in this study.
- 303
- 304 Conflict of Interest
- 305 The authors have no conflict of interest to report.
- 306
- 307 Author contributions statement
- 308 CG, PB, MS and TK conceived the study. CG, JC, KW designed the experiments. CG, and PB supervised
- 309 the study. DT., ES., CWD, JM., and PB performed or contributed to the sample collection and
- 310 preparation. MS performed the dog sample preparation, dog training and data collection, with
- 311 assistance from JS. SM performed statistical analysis. NJR wrote the manuscript, with input from
- 312 JJD. All authors commented and contributed to the final version of manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

313 314					
315	Data availability				
316 317	The data supporting the findings of this study are openly available at the University of Bristol data repository, <u>data.bris</u> , at <u>https://doi.org/10.5523/bris.2ffiar75hr0b82ottk9axxh44i</u>				
318					
319					
320	References				
321 322 323	 Kalia LV, Lang AE (2015) Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. PMID: 25904081. Ali K, Morris HR (2015) Parkinson's disease: chameleons and mimics. <i>Practical neurology</i> 45(4), pp. 14–25. 				
324 325	neurology, 15(1), pp.14-25. 3. Schootemeijer S, van der Kolk NM, Bloem BR, de Vries NM (2020) Current Perspectives on				
326 327	Aerobic Exercise in People with Parkinson's Disease. Neurotherapeutics 17, 1418–1433 https://doi.org/10.1007/s13311-020-00904-8				
328 329 330	 Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism & Related Disorders. 2014 Aug;20(8):840-844. DOI: 10.1016/j.parkreldis.2014.04.019. PMID: 24816002 				
331 332 333	 Gumber A, Ramaswamy B, Ibbotson R, Ismail M, Thongchundee O, Harrop D, Allmark P, Rau A (2017) Economic, Social and Financial Cost of Parkinson's on Individuals, Carers and their Families in the UK. Project Report. Centre for Health and Social Care Research, Sheffield 				
334	Hallam University.				
335 336	6. He R, Yan X, Guo J, Xu Q, Tang B, Sun Q (2018) Recent Advances in Biomarkers for Parkinson's Disease. Frontiers in aging neuroscience, 10, 305.				
337 338 339	 Del Tredici K, Braak H. Review: sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol. 2016 Feb;42(1):33-50. doi: 10.1111/nan.12298. 				
340 341	 Krestin D (1927) The Seborrhoeic Facies as a Manifestation of Post-Encephalitic Parkinsonism and Allied Disorders. QJM , os-21 (81), 177–186. 10.1093/qjmed/os-21.81.177 				
342 343 344	 Ravn Jørgensen AH, Thyssen JP, Egeberg A (2017) Skin disorders in Parkinson's disease: potential biomarkers and risk factors. <i>Clin., Cosmet. Invest. Dermatol.</i> 2017, 10, 87–92. 10.2147/CCID.S130319. 				
345 346 347	 Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M, Kunath T, Goodacre R (2019) Discovery of volatile biomarkers of Parkinson's disease from sebum. ACS Central Science, 5(4), pp.599-606. 				
348 349 350	11. Sinclair E, Trivedi DK, Sarkar D, Walon-Doyle C., Milne J, Kunath T, Rijis AM, de Bie RMA, Goodacre R, Silverdale M, Barran P. (2021) Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. <i>Nat Commun</i> 12 , 1592.				
351 352	 Cone TE (1968) Diagnosis and treatment: some diseases, syndromes and conditions associated with an unusual odour. Pediatrics, Springfield, 41, 993. 				
353 354	 Liddell K Smell as a diagnostic marker. (1976) Postgrad Med J, 52(605):136-138, 01 Mar 1970 Liddell K, White JE (1975) The smell of cancer. British Journal of Dermatology, 92, 215. 				
355	15. Brass A (1970) Odour of sanity. Journal of the American Medical Association, 212, 472.				

356	16.	Smith K, Thompson GF, Koster HD (1969) Sweat in schizophrenic patients: identification of
357		the odorous substance. Science, 166, 398
358	17.	Smith K, Sines JO (1960) Demonstration of a peculiar odor in the sweat of schizophrenic
359		patients. Archives of General Psychiatry, 2, 184.
360	18.	Pirrone F, Piotti P, Galli M, Gasparri R, La Spina A, Spaggiari L, Albertini M (2023) Sniffer dogs
361		performance is stable over time in detecting COVID-19 positive samples and agrees with the
362		rapid antigen test in the field. Scientific Reports, 13(1).
363	19.	Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M,
364		Kunath T, Goodacre R (2019) Discovery of volatile biomarkers of Parkinson's disease from
365		sebum. ACS Central Science, 5(4), pp.599-606
366	20	Rooney N (2016) A medical detection role for dogs International Animal Health
	20.	• • • •
367	24	Journal. 3, 4, 42
368	21.	Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, Church MRT, Church
369		JT (2004) Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ
370		329: 712.
371	22.	Guest C, Pinder M, Doggett M, Squires C, Affara M, Kandeh B, Dewhirst S, Morant SV,
372		D'Alessandro U, Logan JG., Lindsay SW (2019) Trained dogs identify people with malaria
373		parasites by their odour. The Lancet Infectious Diseases, 19(6): .578-580.
374	23.	Vesga O, Agudelo M, Valencia-Jaramillo AF, Mira-Montoya A, Ossa-Ospina F, Ocampo E,
375		Čiuoderis K, Pérez L, Cardona A, Aguilar Y, Agudelo Y, Hernández-Ortiz JP, Osorio JE (2021)
376		Highly sensitive scent-detection of COVID-19 patients in vivo by trained dogs. PLoS One.
377		16(9):e0257474. doi: 10.1371/journal.pone.0257474. PMID: 34587181; PMCID:
378		PMC8480816.
379	24.	Rooney NJ, Morant S, Guest C (2013) Investigation into the Value of Trained Glycaemia Alert
380		Dogs to Clients with Type I Diabetes PLoS ONE. 10.1371/journal.pone.0069921
381	25.	Rooney N, Guest C, Swanson L, Morant S (2019) How effective are trained dogs at alerting
382		their owners to changes in blood glycaemic levels? Variations in performance of glycaemia
383		alert dogs PLoS ONE. 14, 1, 16 p., e0210092.
384	26.	Wilson CH, Kane S, Morant SV, Guest CM, Rooney NJ (2020) Diabetes Alert Dogs: objective
385		behaviours shown during periods of owner glucose fluctuation and stability Appl Anim Behav
386	27	Sci. 223, 10 p., 104915.
387 388	27.	Wilson C, Morant S, Kane S, Pesterfield C, Guest C, Rooney NJ. (2019)An Owner- Independent Investigation of Diabetes Alert Dog Performance Frontiers in Veterinary
389		Science.
390	28	Gao CQ, Wang SN, Wang MM, Li JJ, Qiao JJ, Huang JJ, Zhang XX, Xiang YQ, Xu Q, Wang JL, Liu
391	20.	ZH, Wang JG, Chen ZH, Hu PA, Song Z, Gu SJ, Zhang RX, Lei LF, Zhan KB, Long YT, Zhang Y, Ye
392		M, Zhong Z, Liu YB, Zhang C, He ZM, Fang X, Peng JG, Wang CY, Xu H, Xia BH, Shen L, Tang BS,
393		Zheng CW, Li YA, Guo JF (2022)Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's
394		Disease: A Diagnostic Accuracy Study. Mov Disord. 37(9):1807-1816. doi:
395		10.1002/mds.29180.
396	29.	Guest C, Harris R, Anjum I, Concha A, Rooney NJ (2020) A lesson in standardisation -subtle
397		aspects of the processing of samples can greatly affect dogs' learning: subtle aspects of the
398	• •	processing of samples can greatly affect dogs' learning Frontiers in Veterinary Science.
399	30.	Pochi PE, Strauss JS, Mescon H (1962). Sebum production and fractional 17-ketosteroid
400 401	21	excretion in parkinsonism. J. Invest. Dermatol. 38 , 45–51 Button II. Cartlidge M. Cartlidge NEE Shuster S (1972) Solum excretion in Parkinsonism
401 402	51.	Burton JL, Cartlidge M, Cartlidge NEF Shuster S (1972) Sebum excretion in Parkinsonism. British Journal of Dermatology 88 , 263–266
402		British Joannal of Dermatology 00, 203-200

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23296924; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- 403 32. Gadbois S, Reeve C (2016). The semiotic canine: scent processing dogs as research assistants
- 404 in biomedical and environmental research. Dog Behaviour, 2, 26–32. DOI:
- 405 http://dx.doi.org/10.4454/db.v2i3.43